查詢結果分析
相關文獻
- Rituximab-induced Severe Pulmonary Disease
- 簡介體外照光化學療法的現在與未來
- Steroid-responsive Primary T-cell Lymphoma in the Brain: Report of a Case
- Steroid Refractory Interstitial Pneumonitis in a Patient with Juvenile Dermatomyositis
- De novo CD5-positive Diffuse Large B-cell Lymphoma Presenting with Leg Edema
- Gefitinib引起的急性間質性肺部疾病案例報告
- Cytomegalovirus Infection in Non-transplant Patients with Hematologic Neoplasms: A Case Series
- 消化性潰瘍與慢性阻塞性肺部疾病之相互關係
- Bronchiolitis Obliterans Organizing Pneumonia
- Pneumocystis Jiroveci Pneumonia in Patients with Non-Hodgkin's Lymphoma Receiving Chemotherapy Containing Rituximab
頁籤選單縮合
題名 | Rituximab-induced Severe Pulmonary Disease=Rituximab引致嚴重肺部疾病 |
---|---|
作者 | 鍾為邦; 吳尚殷; 葉裕民; 陳雅萍; 邱威鑫; 林鵬展; 蘇文彬; 顏家瑞; 蘇五洲; 陳彩雲; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 29:2 2013.06[民102.06] |
頁次 | 頁79-83 |
分類號 | 418.31 |
關鍵詞 | 莫須瘤; 淋巴瘤; 肺部疾病; 間質性肺炎; 類固醇; Rituximab; Lymphoma; Pulmonary disease; Interstitial pneumonitis; Steroid; |
語文 | 英文(English) |
中文摘要 | 過去十數年間,莫須瘤已被廣泛運用於治療 CD20 陽性之 B 細胞淋巴瘤。根據全世 界超過一百萬人的使用經驗,注射莫須瘤是相當安全與可耐受的。相關的副作用通常輕 微,且大多數為發燒或寒顫等與輸注相關的反應,這一類的反應可藉由放慢輸注速率與 給予前導藥物來預防,不過即便如此,仍偶有報導因莫須瘤而引發的嚴重肺部疾病,其 發生率介於 0.01%-0.03%之間。我們於此做一位患者的個案報告,病患為 77 歲男性,在 接受第二次莫須瘤注射後旋即引發間質性肺炎與呼吸衰竭,細胞激素在此類疾病的致病 機轉上可能具有重要地位,而這些副作用或許可經由適當地縮減腫瘤負荷及施與類固醇 來預防。 |
英文摘要 | Rituximab has been widely used to treat CD20+ B-cell lymphoma for more than ten years. Its safety and tolerability are well established on the basis of data from more than one million patients worldwide. The side effects are usually mild, and mostly are infusion-related reactions (IRRs) such as fever and chills. IRRs can be prevented by slow administration and some premedication. However, rituximab-induced severe pulmonary disease is still occasionally reported, with an occurrence rate of 0.01-0.03%. We herein report a 77-year-old man who presented with interstitial pneumonitis and respiratory failure soon after the second infusion of rituximab. Cytokines may play an important role in the pathogenesis of rituximab-related complications. Such side effects may be prevented by appropriate cytoreduction of the tumor and premedication with steroids. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。